Özlem Öz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Özlem Öz has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Mehmet Burak Mutlu
Detagen Genetic Diseases Evaluation Center, Kayseri, Türkiye
6 shared publications - Fethiye Kılıçaslan
Department of Child and Adolescent Psychiatry, Harran University, Faculty of Medicine, Sanliurfa, Turkey
3 shared publications - Ataman Gönel
SANKO University, Faculty of Medicine, Department of Medical Biochemistry, Gaziantep, Turkey
2 shared publications - Ebru Tuncez
Department of Medical Genetics, Konya City Hospital, Konya, Turkey
2 shared publications - Hakan Gumus
Erciyes University Faculty of Medicine, Department of Pediatric Neurology, Kayseri, Turkey
2 shared publications - Ismail Koyuncu
Harran University
2 shared publications
Latest Publications
- 17 November 2026
- Published by Taylor & Francis in Journal of Neurogenetics
- p. 1-10
Whole-exome sequencing reveals the neurogenetic spectrum of pediatric epilepsy in Türkiye
- 17 November 2026
- Published by Taylor & Francis in Journal of Neurogenetics
- p. 1-10
Whole-exome sequencing reveals the neurogenetic spectrum of pediatric epilepsy in Türkiye
- Open Access
- 13 October 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Whole-exome sequencing in a Turkish autism spectrum disorder cohort: a retrospective study of molecular diagnostic yield in isolated and complex presentations
Background: Whole-exome sequencing (WES) can identify molecular etiologies in autism spectrum disorder (ASD), particularly when ASD occurs with developmental delay/intellectual disability (DD/ID), epilepsy, dysmorphism, congenital anomalies, or neuroimaging abnormalities. Data on WES yield and candidate-gene findings in Turkish ASD cohorts remain limited. We assessed molecular diagnostic yield and variant spectrum in a Turkish clinical ASD cohort, with comparison of isolated and complex ASD presentations. Methods: This retrospective cohort study included 320 individuals with ASD evaluated by WES between 2020 and 2025. Patients were classified as having isolated or complex ASD based on co-occurring neurodevelopmental, neurological, dysmorphic, congenital, or systemic findings. Variants were interpreted using ACMG/AMP criteria. Established molecular diagnoses required pathogenic or likely pathogenic (P/LP) variants associated with OMIM-defined disorders or occurring in genes with definitive, strong, or moderate ClinGen evidence for a neurodevelopmental disorder (NDD). Categorical comparisons used two-sided Fisher’s exact test. Results: Established molecular diagnoses were identified in 104/320 patients (32.5%; 95% confidence interval [CI], 27.4–37.9%), including 2/22 patients with isolated ASD (9.1%; 95% CI, 1.1–29.2%) and 102/298 patients with complex ASD (34.2%; 95% CI, 28.9–39.9%; p = 0.017). An additional 12 patients had P/LP variants in candidate or emerging genes, resulting in an overall P/LP finding rate of 116/320 (36.3%; 95% CI, 31.0–41.8%). Variants of uncertain significance were identified in 147 patients, while no ASD/NDD-related variant was identified in 57 patients. Conclusions: WES supports etiological clarification in clinically complex ASD. Established molecular diagnoses were substantially more frequent in complex than isolated ASD. Candidate and emerging gene findings should be reported separately and interpreted as hypothesis-generating.
- 13 October 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessWhole-exome sequencing in a Turkish autism spectrum disorder cohort: a retrospective study of molecular diagnostic yield in isolated and complex presentations
Background: Whole-exome sequencing (WES) can identify molecular etiologies in autism spectrum disorder (ASD), particularly when ASD occurs with developmental delay/intellectual disability (DD/ID), epilepsy, dysmorphism, congenital anomalies, or neuroimaging abnormalities. Data on WES yield and candidate-gene findings in Turkish ASD cohorts remain limited. We assessed molecular diagnostic yield and variant spectrum in a Turkish clinical ASD cohort, with comparison of isolated and complex ASD presentations. Methods: This retrospective cohort study included 320 individuals with ASD evaluated by WES between 2020 and 2025. Patients were classified as having isolated or complex ASD based on co-occurring neurodevelopmental, neurological, dysmorphic, congenital, or systemic findings. Variants were interpreted using ACMG/AMP criteria. Established molecular diagnoses required pathogenic or likely pathogenic (P/LP) variants associated with OMIM-defined disorders or occurring in genes with definitive, strong, or moderate ClinGen evidence for a neurodevelopmental disorder (NDD). Categorical comparisons used two-sided Fisher’s exact test. Results: Established molecular diagnoses were identified in 104/320 patients (32.5%; 95% confidence interval [CI], 27.4–37.9%), including 2/22 patients with isolated ASD (9.1%; 95% CI, 1.1–29.2%) and 102/298 patients with complex ASD (34.2%; 95% CI, 28.9–39.9%; p = 0.017). An additional 12 patients had P/LP variants in candidate or emerging genes, resulting in an overall P/LP finding rate of 116/320 (36.3%; 95% CI, 31.0–41.8%). Variants of uncertain significance were identified in 147 patients, while no ASD/NDD-related variant was identified in 57 patients. Conclusions: WES supports etiological clarification in clinically complex ASD. Established molecular diagnoses were substantially more frequent in complex than isolated ASD. Candidate and emerging gene findings should be reported separately and interpreted as hypothesis-generating.
- Open Access
- 9 September 2026
- Published by Wiley in Cell Biochemistry and Function
- Vol. 44 (9) , e70304
Melatonin Protects BEAS‐2B Cells Against Hypoxia/Reoxygenation‐Induced Injury By Reducing MLKL Levels, Suppressing Oxidative Stress and Preserving Mitochondrial Function
Necroptosis has been demonstrated to play a role in the process of lung ischemia‐reperfusion injury (LIRI) in a variety of clinical conditions, including cardiopulmonary bypass and pulmonary embolism. Melatonin has been reported to exert a protective role by reducing oxidative stress and acute inflammatory reactions in LIRI. However, the effect of melatonin on necroptosis in LIRI remains unclear. The aim of this study was to investigate whether the protective effects of melatonin against H/R‐induced injury are associated with modulation of necroptosis and related changes in mitochondrial function and oxidative stress. The cells were exposed to H/R (16/4 h) or normoxia, in the absence or presence of 2.5 µM melatonin. Cell viability was determined by the MTT method, while morphological changes in BEAS‐2B cells resulting from H/R exposure were evaluated by fluorescence microscopy using acridine orange/ethidium bromide (AO/EtBr) staining. Mechanistic analyses, including flow cytometry‐based cell cycle assessment, apoptosis detection (Annexin V‐FITC), mitochondrial membrane potential evaluation (JC‐1), and reactive oxygen species (ROS) measurements, were performed on BEAS‐2B cells. The level of the mixed lineage kinase domain‐like pseudokinase (MLKL), a key component of the necroptosis complex, was also quantified using an enzyme‐linked immunosorbent assay. In addition, the ATP, pH, and lactate levels were determined. The findings indicated that melatonin treatment reduced the H/R‐induced increase in the percentage of necrotic cells and increased the percentage of viable cells ( p < 0.05). In addition, melatonin treatment reduced the increase in MLKL, ROS, and lactate levels, preserved mitochondrial membrane integrity, and increased intracellular ATP levels in BEAS‐2B cells exposed to H/R ( p < 0.05). In conclusion, this study suggests that melatonin protects BEAS‐2B cells against H/R‐induced injury, and that this protective effect may be associated with reduced oxidative stress, preservation of mitochondrial function, and suppression of necroptosis‐related signaling.
- 9 September 2026
- Published by Wiley in Cell Biochemistry and Function
- Vol. 44 (9) , e70304
Open AccessMelatonin Protects BEAS‐2B Cells Against Hypoxia/Reoxygenation‐Induced Injury By Reducing MLKL Levels, Suppressing Oxidative Stress and Preserving Mitochondrial Function
Necroptosis has been demonstrated to play a role in the process of lung ischemia‐reperfusion injury (LIRI) in a variety of clinical conditions, including cardiopulmonary bypass and pulmonary embolism. Melatonin has been reported to exert a protective role by reducing oxidative stress and acute inflammatory reactions in LIRI. However, the effect of melatonin on necroptosis in LIRI remains unclear. The aim of this study was to investigate whether the protective effects of melatonin against H/R‐induced injury are associated with modulation of necroptosis and related changes in mitochondrial function and oxidative stress. The cells were exposed to H/R (16/4 h) or normoxia, in the absence or presence of 2.5 µM melatonin. Cell viability was determined by the MTT method, while morphological changes in BEAS‐2B cells resulting from H/R exposure were evaluated by fluorescence microscopy using acridine orange/ethidium bromide (AO/EtBr) staining. Mechanistic analyses, including flow cytometry‐based cell cycle assessment, apoptosis detection (Annexin V‐FITC), mitochondrial membrane potential evaluation (JC‐1), and reactive oxygen species (ROS) measurements, were performed on BEAS‐2B cells. The level of the mixed lineage kinase domain‐like pseudokinase (MLKL), a key component of the necroptosis complex, was also quantified using an enzyme‐linked immunosorbent assay. In addition, the ATP, pH, and lactate levels were determined. The findings indicated that melatonin treatment reduced the H/R‐induced increase in the percentage of necrotic cells and increased the percentage of viable cells ( p < 0.05). In addition, melatonin treatment reduced the increase in MLKL, ROS, and lactate levels, preserved mitochondrial membrane integrity, and increased intracellular ATP levels in BEAS‐2B cells exposed to H/R ( p < 0.05). In conclusion, this study suggests that melatonin protects BEAS‐2B cells against H/R‐induced injury, and that this protective effect may be associated with reduced oxidative stress, preservation of mitochondrial function, and suppression of necroptosis‐related signaling.
- 14 August 2026
- Published by Springer Nature in Journal of Human Genetics
- Vol. 71 (11) , 731-740
Biallelic SLC20A2 loss-of-function in severe early-onset neurodevelopmental disorder with brain calcification
- 14 August 2026
- Published by Springer Nature in Journal of Human Genetics
- Vol. 71 (11) , 731-740
Biallelic SLC20A2 loss-of-function in severe early-onset neurodevelopmental disorder with brain calcification
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 3130383
Structural Variant and Repeat Expansion Findings Identified by Optical Genome Mapping in Complex Autism Spectrum Disorder With Concomitant Neurodevelopmental Disorders
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and interaction, along with restricted, repetitive patterns of behavior, interests, or activities. Single‐nucleotide variants (SNVs) and structural variants (SVs), including copy‐number variants (CNVs), have been reported as important contributors to the genetic basis of ASD. In this study, we evaluated the diagnostic contribution of optical genome mapping (OGM) as a complementary cytogenomic approach in a selected ASD cohort enriched for complex ASD with developmental delay/intellectual disability (DD/ID) and/or additional neurodevelopmental or syndromic features. We retrospectively evaluated 34 individuals with ASD who underwent OGM analysis, most of whom had concomitant DD/ID and/or additional neurological, congenital, or syndromic features. Confirmed pathogenic (P) or likely pathogenic (LP) findings were identified in 7/34 individuals (20.6%), and one additional unconfirmed OGM‐only duplication was provisionally interpreted as pathogenic. Overall, confirmed or provisional P/LP findings were observed in 8/34 individuals (23.5%), all of whom had complex ASD with DD/ID and/or additional neurodevelopmental or syndromic features. OGM‐detected findings were confirmed by orthogonal methods whenever clinically and technically feasible, and segregation analyses were performed when samples were available. These results suggest that OGM may add value to integrated genetic testing workflows for selected individuals with complex ASD, particularly when SVs, complex chromosomal rearrangements, or FMR1 full‐mutation repeat expansions are clinically suspected or insufficiently resolved by conventional approaches.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 3130383
Open AccessStructural Variant and Repeat Expansion Findings Identified by Optical Genome Mapping in Complex Autism Spectrum Disorder With Concomitant Neurodevelopmental Disorders
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and interaction, along with restricted, repetitive patterns of behavior, interests, or activities. Single‐nucleotide variants (SNVs) and structural variants (SVs), including copy‐number variants (CNVs), have been reported as important contributors to the genetic basis of ASD. In this study, we evaluated the diagnostic contribution of optical genome mapping (OGM) as a complementary cytogenomic approach in a selected ASD cohort enriched for complex ASD with developmental delay/intellectual disability (DD/ID) and/or additional neurodevelopmental or syndromic features. We retrospectively evaluated 34 individuals with ASD who underwent OGM analysis, most of whom had concomitant DD/ID and/or additional neurological, congenital, or syndromic features. Confirmed pathogenic (P) or likely pathogenic (LP) findings were identified in 7/34 individuals (20.6%), and one additional unconfirmed OGM‐only duplication was provisionally interpreted as pathogenic. Overall, confirmed or provisional P/LP findings were observed in 8/34 individuals (23.5%), all of whom had complex ASD with DD/ID and/or additional neurodevelopmental or syndromic features. OGM‐detected findings were confirmed by orthogonal methods whenever clinically and technically feasible, and segregation analyses were performed when samples were available. These results suggest that OGM may add value to integrated genetic testing workflows for selected individuals with complex ASD, particularly when SVs, complex chromosomal rearrangements, or FMR1 full‐mutation repeat expansions are clinically suspected or insufficiently resolved by conventional approaches.
- 25 December 2025
- Published by Harran Universitesi Tip Fakultesi Dergisi in Harran Üniversitesi Tıp Fakültesi Dergisi
- Vol. 22 (4) , 698-701
Türkiye’nin Güneydoğu Anadolu Bölgesindeki Distoni Genetiği
Amaç: Distoni, distoninin belirgin bir özellik olduğu hiperkinetik hareket bozukluklarını tanımlamak için kullanılan bir terimdir. Etiyolojiye bağlı olarak distoni, edinilmiş, kalıtsal veya idiyopatik olabilir. Bu yollarda genellikle rol oynayan distoni genleri, izole, kompleks ve kombine distoni genleri olarak sınıflandırılır. Bu çalışmada, 60 hastada distoninin genetik nedenlerini tüm eksom dizileme (WES) ile araştırdık. Elde edilen sonuçların genotip-fenotip korelasyonu yapıldı. Materyal ve Metod: Çalışmaya, 2021 ile 2025 yılları arasında Harran Üniversitesi Tıp Fakültesi Hastanesi’ne sevk edilen 60 hasta (25 kadın, 35 erkek) dahil edildi. Hastalar distoni semptomlarının varlığına göre seçildi. WES uyguladık ve önerilen kılavuzlara göre varyantları değerlendirdik. Bulgular: WES analizi, kohortun 17 hastasında (yaklaşık %28) patojenik veya muhtemelen patojenik mutasyonların varlığını ortaya çıkardı. Otuz yedi hasta (yaklaşık %62) klinik önemi belirsiz varyantlar (VUS) sergiledi. 6 hastada (%10) WES, distoni ile ilişkili herhangi bir varyasyon saptamadı. Sonuç: Bu çalışma, Güneydoğu Anadolu Bölgesi’nde distoninin tanı ve tedavisinde genetik testlerin önemli rolünü vurgulamaktadır. Spesifik genetik varyantların tanımlanması, kişiselleştirilmiş tedavi stratejilerinin uygulanmasını kolaylaştırır ve bu da tedavi sonuçlarını iyileştirme ve yan etkileri azaltma potansiyeline sahiptir.
- 25 December 2025
- Published by Harran Universitesi Tip Fakultesi Dergisi in Harran Üniversitesi Tıp Fakültesi Dergisi
- Vol. 22 (4) , 698-701
Türkiye’nin Güneydoğu Anadolu Bölgesindeki Distoni Genetiği
Amaç: Distoni, distoninin belirgin bir özellik olduğu hiperkinetik hareket bozukluklarını tanımlamak için kullanılan bir terimdir. Etiyolojiye bağlı olarak distoni, edinilmiş, kalıtsal veya idiyopatik olabilir. Bu yollarda genellikle rol oynayan distoni genleri, izole, kompleks ve kombine distoni genleri olarak sınıflandırılır. Bu çalışmada, 60 hastada distoninin genetik nedenlerini tüm eksom dizileme (WES) ile araştırdık. Elde edilen sonuçların genotip-fenotip korelasyonu yapıldı. Materyal ve Metod: Çalışmaya, 2021 ile 2025 yılları arasında Harran Üniversitesi Tıp Fakültesi Hastanesi’ne sevk edilen 60 hasta (25 kadın, 35 erkek) dahil edildi. Hastalar distoni semptomlarının varlığına göre seçildi. WES uyguladık ve önerilen kılavuzlara göre varyantları değerlendirdik. Bulgular: WES analizi, kohortun 17 hastasında (yaklaşık %28) patojenik veya muhtemelen patojenik mutasyonların varlığını ortaya çıkardı. Otuz yedi hasta (yaklaşık %62) klinik önemi belirsiz varyantlar (VUS) sergiledi. 6 hastada (%10) WES, distoni ile ilişkili herhangi bir varyasyon saptamadı. Sonuç: Bu çalışma, Güneydoğu Anadolu Bölgesi’nde distoninin tanı ve tedavisinde genetik testlerin önemli rolünü vurgulamaktadır. Spesifik genetik varyantların tanımlanması, kişiselleştirilmiş tedavi stratejilerinin uygulanmasını kolaylaştırır ve bu da tedavi sonuçlarını iyileştirme ve yan etkileri azaltma potansiyeline sahiptir.
- 11 November 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 260, 109237
Stroke in pregnancy and postpartum: Etiology, incidence, and risk factors in a tertiary care cohort
- 11 November 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 260, 109237
Stroke in pregnancy and postpartum: Etiology, incidence, and risk factors in a tertiary care cohort
- Open Access
- 26 March 2025
- Published by Harran Universitesi Tip Fakultesi Dergisi in Harran Üniversitesi Tıp Fakültesi Dergisi
- Vol. 22 (1) , 32-35
Neuroradiologic Findings Associated with Tuberous Sclerosis Complex: A Comprehensive Analysis of 24 Cases
Background: This study aims to comprehensively analyze the radiological findings of 24 TSC patients to determine the radiological profile of the disease and potential diagnostic and therapeutic imp-lications. Materials and Methods: This retrospective study was approved by the Ethics Committee of Harran University. A total of 24 genetically diagnosed TSC patients who underwent brain MRI between 2020-2024 were included. Imaging was performed using a 3 Tesla MRI scanner, employing T2 IDEAL, 3D T1 VIBRANT, and contrast-enhanced T1 sequences. Data were analyzed using IBM SPSS Statistics software, focusing on demographic characteristics and radiological findings. Results: The study included 24 TSC patients (14 males, 10 females) with a mean age of 8.43±10.24 years (range: 1-46 years). Cortical/subcortical tubers and subependymal hamartomas were identi-fied in all patients (100%). Radial bands were observed in 83.3%, infarctions in 50%, and corpus callosum dysgenesis in 41.6%. Subependymal giant cell astrocytoma (SGCA) was present in 12.5% of cases, while arachnoid cysts were noted in 20.8%. Conclusions: This study revealed a higher CNS involvement rate in TSC patients compared to the literature, with a higher prevalence among male patients. These findings emphasize the importan-ce of detailed radiological and clinical evaluations in understanding the disease. Changes in radio-logical findings with age and disease progression can contribute to optimizing treatment protocols.
- 26 March 2025
- Published by Harran Universitesi Tip Fakultesi Dergisi in Harran Üniversitesi Tıp Fakültesi Dergisi
- Vol. 22 (1) , 32-35
Open AccessNeuroradiologic Findings Associated with Tuberous Sclerosis Complex: A Comprehensive Analysis of 24 Cases
Background: This study aims to comprehensively analyze the radiological findings of 24 TSC patients to determine the radiological profile of the disease and potential diagnostic and therapeutic imp-lications. Materials and Methods: This retrospective study was approved by the Ethics Committee of Harran University. A total of 24 genetically diagnosed TSC patients who underwent brain MRI between 2020-2024 were included. Imaging was performed using a 3 Tesla MRI scanner, employing T2 IDEAL, 3D T1 VIBRANT, and contrast-enhanced T1 sequences. Data were analyzed using IBM SPSS Statistics software, focusing on demographic characteristics and radiological findings. Results: The study included 24 TSC patients (14 males, 10 females) with a mean age of 8.43±10.24 years (range: 1-46 years). Cortical/subcortical tubers and subependymal hamartomas were identi-fied in all patients (100%). Radial bands were observed in 83.3%, infarctions in 50%, and corpus callosum dysgenesis in 41.6%. Subependymal giant cell astrocytoma (SGCA) was present in 12.5% of cases, while arachnoid cysts were noted in 20.8%. Conclusions: This study revealed a higher CNS involvement rate in TSC patients compared to the literature, with a higher prevalence among male patients. These findings emphasize the importan-ce of detailed radiological and clinical evaluations in understanding the disease. Changes in radio-logical findings with age and disease progression can contribute to optimizing treatment protocols.
- 30 November 2024
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 85 (1)
Investigation of chromosomal anomalies and copy number variations in children diagnosed with autism spectrum disorder by array CGH method
This study aimed to identify the chromosomal anomalies and copy number variations (CNVs) in autism spectrum disorder (ASD) and to provide genotype/phenotype correlations. Fifty‐four patients diagnosed with ASD between March 2021 and June 2022 were included in the study. Patients were evaluated by cytogenetic analysis and array comparative genomic hybridisation analysis (aCGH). The structural and numerical chromosomal anomaly was detected in 3.7%, and the CNVs were identified in 18.52% of patients. Of the CNVs detected, 27.3% were identified as pathogenic, 18.2% as likely pathogenic and 54.5% as VUS. The copy number gain rate of the detected CNVs was higher than the copy number losses rate, 70% and 30% respectively. As an important finding in the study, a new pathogenic CNV with a 6.3‐mb copy number gain in the 3p22.3p22.2 region, whose gene region had not been previously defined in OMIM, was detected. Identifying a genetic aetiology may provide clinicians with more information about disease prognosis and risk of recurrence.
- 30 November 2024
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 85 (1)
Investigation of chromosomal anomalies and copy number variations in children diagnosed with autism spectrum disorder by array CGH method
This study aimed to identify the chromosomal anomalies and copy number variations (CNVs) in autism spectrum disorder (ASD) and to provide genotype/phenotype correlations. Fifty‐four patients diagnosed with ASD between March 2021 and June 2022 were included in the study. Patients were evaluated by cytogenetic analysis and array comparative genomic hybridisation analysis (aCGH). The structural and numerical chromosomal anomaly was detected in 3.7%, and the CNVs were identified in 18.52% of patients. Of the CNVs detected, 27.3% were identified as pathogenic, 18.2% as likely pathogenic and 54.5% as VUS. The copy number gain rate of the detected CNVs was higher than the copy number losses rate, 70% and 30% respectively. As an important finding in the study, a new pathogenic CNV with a 6.3‐mb copy number gain in the 3p22.3p22.2 region, whose gene region had not been previously defined in OMIM, was detected. Identifying a genetic aetiology may provide clinicians with more information about disease prognosis and risk of recurrence.
- Open Access
- 11 November 2024
- Published by Pamukkale University in Pamukkale Medical Journal
Investigation of the Effects of Biotinidase Deficiency on Plasma Cholinesterase Activity
Purpose: Biotinidase deficiency (BD) is a rare autosomal recessive metabolic disorder that impairs the body's ability to recycle biotin, a crucial coenzyme for carboxylase enzymes involved in various metabolic processes. This study aims to evaluate the effects of biotinidase deficiency on cholinesterase activity in plasma, hypothesizing that the metabolic disruptions caused by inadequate biotin recycling may lead to alterations in cholinesterase function. Materials and methods: Plasma samples were collected from 73 individuals categorized into four genetic groups: wild type (n = 12), heterozygous (n = 30), homozygous (n = 19), and compound heterozygous (n = 12). Cholinesterase activity was measured using a colorimetric method. Results: The study discovered that the cholinesterase activity of the Heterozygous group was higher than the homozygous group (p = 0.0356). Additionally, cholinesterase activity was significantly lower in homozygous and compound heterozygous people than in wild and heterozygous groups (p = 0.0272). The statistically significant changes suggested a relationship between biotinidase deficiency and altered cholinergic activity. Conclusion: The findings indicate that biotinidase deficiency, particularly in its severe variants, may cause considerable reductions in cholinesterase activity, contributing to the neurological symptoms found in affected patients. More studies are needed to investigate the processes behind this association and develop strategies for reducing the effects of BD on cholinesterase activity and neurological health.
- 11 November 2024
- Published by Pamukkale University in Pamukkale Medical Journal
Open AccessInvestigation of the Effects of Biotinidase Deficiency on Plasma Cholinesterase Activity
Purpose: Biotinidase deficiency (BD) is a rare autosomal recessive metabolic disorder that impairs the body's ability to recycle biotin, a crucial coenzyme for carboxylase enzymes involved in various metabolic processes. This study aims to evaluate the effects of biotinidase deficiency on cholinesterase activity in plasma, hypothesizing that the metabolic disruptions caused by inadequate biotin recycling may lead to alterations in cholinesterase function. Materials and methods: Plasma samples were collected from 73 individuals categorized into four genetic groups: wild type (n = 12), heterozygous (n = 30), homozygous (n = 19), and compound heterozygous (n = 12). Cholinesterase activity was measured using a colorimetric method. Results: The study discovered that the cholinesterase activity of the Heterozygous group was higher than the homozygous group (p = 0.0356). Additionally, cholinesterase activity was significantly lower in homozygous and compound heterozygous people than in wild and heterozygous groups (p = 0.0272). The statistically significant changes suggested a relationship between biotinidase deficiency and altered cholinergic activity. Conclusion: The findings indicate that biotinidase deficiency, particularly in its severe variants, may cause considerable reductions in cholinesterase activity, contributing to the neurological symptoms found in affected patients. More studies are needed to investigate the processes behind this association and develop strategies for reducing the effects of BD on cholinesterase activity and neurological health.